DOI: 10.1055/s-00000030

Der Klinikarzt

References

De Placido S, Gallo C, De Laurentiis M. et al.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

Lancet Oncol 2018;
19: 474-485

Download Bibliographical Data

Search in:
Access:
Access: